The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Prospective Clinical Research Of Radiation Response To High-dose Radiotherapy In Lung Tumours And Surrounding Normal Tissue Using Functional Imaging Biomarker Assessments
Funder
National Health and Medical Research Council
Funding Amount
$120,275.00
Summary
Radiotherapy is a potentially curative treatment for cancers of the lung. To improve outcomes, modern research efforts have focussed on radiotherapy dose escalation. However a major limitation to dose escalation is the associated toxicity to the lung. At present, the mechanisms of lung toxicity are incompletely understood. This research will investigate biomarkers of radiation response in patients receiving high-dose radiotherapy to the lung by using state-of-the-art scanning techniques.
Bowel cancer is the 2nd most common cause of cancer death in Australia. Rectal cancer represents 40% of these, and is more common in the elderly who are frequently unable to tolerate chemoradiation therapy. The Mutated in Colorectal Cancer gene (MCC) could become a predictor to chemoradiotherapy in up to 30% of these patients. A defective MCC in tumours can predict a good response to this treatment. Our project will potentially identify patients that are more sensitive to chemoradiotherapy and l ....Bowel cancer is the 2nd most common cause of cancer death in Australia. Rectal cancer represents 40% of these, and is more common in the elderly who are frequently unable to tolerate chemoradiation therapy. The Mutated in Colorectal Cancer gene (MCC) could become a predictor to chemoradiotherapy in up to 30% of these patients. A defective MCC in tumours can predict a good response to this treatment. Our project will potentially identify patients that are more sensitive to chemoradiotherapy and lead to a personalized treatment of rectal cancer.Read moreRead less
Overcoming Radiation Resistance In Glioblastoma With Novel Metabolic Modulations
Funder
National Health and Medical Research Council
Funding Amount
$62,554.00
Summary
Aim 1 is to document the pathological, surgical, radiotherapy and chemotherapy patterns of care in the Australian setting using the AGOG (Australian Genomics and Clinical Outcomes of Glioma) database. The second aim to develop non-invasive imaging biomarkers which can be used to monitor treatment efficacy. The third aim is to improve outcomes using drug and radiation combination therapy. in the treatment of high grade gliomas.
Exploiting Genetic Analysis To Predict Response And To Discover Novel Molecular Targeted Therapies For Rectal Cancer
Funder
National Health and Medical Research Council
Funding Amount
$83,871.00
Summary
Bowel cancer is a significant health burden in Australia. Currently it is difficult to predict which bowel cancer will shrink with standard therapy (chemoradiotherapy). Similarly, patients whose cancer remain the same or increase in size during treatment, there are no other new options available to them. In this research, I intend to find a model that could predict patient’s treatment pathway and identify alternative therapy for patients who did not respond to standard therapy.
Determining The Genetic Basis Of Skeletal Dysplasias Using Next Generation Sequencing
Funder
National Health and Medical Research Council
Funding Amount
$110,068.00
Summary
Osteoporosis is a common condition in Australia, yet treatment options are still limited. Study of rare genetic bone conditions known collectively as skeletal dysplasias have already led to the development of two new osteoporosis drug treatments. My project aims to identify the causative gene for several skeletal dysplasias, and to determine how these genes are involved in the development and maintenance of bone. This knowledge may then translate into new osteoporosis therapies.
Role Of Proline-rich Tyrosine Kinase 2 (Pyk2) In Ovarian Cancer
Funder
National Health and Medical Research Council
Funding Amount
$85,254.00
Summary
Ovarian cancer is one of the most lethal gynaecological cancers in the developed world. Elevated levels of gonadotropin hormones and cell protein Pyk2 have been implicated in ovarian cancer. Our aim is to determine the role of Pyk2 in growth and metastasis of ovarian cancer when stimulated with gonadotropins. In addition, we aim to identify protein changes which occur in ovarian cancer when stimulated by gonadotropins in order to identify new biomarkers for the disease.
In Vitro And In Vivo Investigation Of Actin Regulation In The Malaria Parasite
Funder
National Health and Medical Research Council
Funding Amount
$92,294.00
Summary
Malaria parasites move in a unique way. They move across cell surfaces and infect human cells using a unique molecular motor that allows them to, literally, glide. The research proposal outlined here is focused on understanding a key part of the motor – the dynamic protein actin – and by understanding how it is regulated develop new potential targets for novel drugs that might stop movement and, therefore, help prevent or treat malaria disease.
Understanding The Pathogenesis, Phenotypic Variation And Risk Prediction Of Childhood Asthma Using Computational Approaches
Funder
National Health and Medical Research Council
Funding Amount
$122,714.00
Summary
Asthma is a common respiratory illness in Australia. It is important to be able to predict who gets asthma, because those who get early treatment tend to fare better. We plan to run complex tests on data collected from hundreds of Australian children. The collected data includes genetic variations, chest infections, and differences in immune responses. From this data we hope to achieve a better understanding of the driving forces behind asthma, and to make better predictions for those at risk.
Dual 68-Gallium/FDG PET Imaging In Neuroendocrine Tumours
Funder
National Health and Medical Research Council
Funding Amount
$75,006.00
Summary
Neuroendocrine tumours (NETs) are uncommon cancers. Low-grade tumours may grow very slowly and not require treatment, but high-grade tumours can grow over weeks and have a poor prognosis. Grade is determined by looking at tissue, but this may vary considerably even in different disease sites in the same patient. Two PET scans (FDG PET and 68Gallium PET) can show high grade and low grade disease respectively, and we plan to investigate their combination in imaging advanced neuroendocrine tumours.
Examining The Role Of Extracellular Myeloperoxidase In The Pathogenesis, Identification And Treatment Of High-risk Unstable And Ruptured Atherosclerotic Plaque
Funder
National Health and Medical Research Council
Funding Amount
$103,356.00
Summary
Vascular inflammation has emerged as a key driver and therapeutic target for stroke and heart attack. Existing diagnostic techniques and treatments do not target inflammation so that residual inflammatory risk remains. There is a need to identify patients with active inflammation who may benefit from treatment. Myeloperoxidase is an inflammatory enzyme abundant in plaque at risk of rupture and subsequent stroke or heart attack and presents as a potential diagnostic tool and therapeutic target.